We're always working to initiate change for patients
This section includes information and helpful resources so you can stay up to date on the latest UroGen innovations, events, news coverage, and more.
UroGen® profile
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urological and specialty cancers because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGel®, a reverse-thermal sustained-release hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained-release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.
Jelmyto® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade intermediate risk non-muscle invasive bladder cancer, are designed to ablate tumors by nonsurgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
Our leadership
News releases
Nov 26, 2024
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
The Study Results are Published in the Journal of Urology Online PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 26, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results
Read storyNov 6, 2024
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
<p>New Drug Application for UGN-102 accepted by US FDA ; PDUFA target action date set for June 13, 2025 JELMYTO ® achieved net product sales of $25.2 million in Q3 2024, compared to $20.9 million in Q3 2023 $254.2 million in cash, cash equivalents and marketable securities as of September 30, 2024</p>
Read storyNov 5, 2024
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
Fireside Chat on November 12, 2024 at 3:00 PM ET PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 5, 2024-- UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will
Read story